<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>safety concerns on FinanClub</title>
    <link>https://finan.club/tags/safety-concerns/</link>
    <description>Recent content in safety concerns on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 12 Aug 2023 05:34:48 +0000</lastBuildDate><atom:link href="https://finan.club/tags/safety-concerns/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>APLS</title>
      <link>https://finan.club/us/apls/</link>
      <pubDate>Sat, 12 Aug 2023 05:34:48 +0000</pubDate>
      
      <guid>https://finan.club/us/apls/</guid>
      <description>score:-69
Chances: Apellis Pharmaceuticals reported better-than-expected second-quarter 2023 results, indicating strong performance in its financials. Positive data on SYFOVRE&amp;rsquo;s reduction of nonsubfoveal GA lesion growth could reflect the potential effectiveness of Apellis&amp;rsquo; products. Equity awards granted to new employees could attract and incentivize talented individuals to join the company, contributing to its growth.</description>
    </item>
    
  </channel>
</rss>
